Effects of Chinese herbal medicine Jiangzhi granule on expressions of liver X receptor a and sterol regulatory element-binding protein-1c in a rat model of non-alcoholic fatty liver disease

Journal of Chinese Integrative Medicine

Volumn 9, Issue 9, 2011, Pages 998-1004

  Yang, Li Li ^a   Wang, Miao ^a   Liu, Tao ^a   Song, Hai Yan ^a   Li, Dong Fei ^b   Zheng, Pei Yong ^a   Liu, Ping ^a   Ji, Guang ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b FUDAN UNIVERSITY PUDONG MEDICAL CENTER   (China)

Author keywords

Antilipemic agents (TCD); Chinese herbal; Drugs; Fatty liver; Liver X receptor ; Rats; Sterol regulatory element binding protein 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FATTY ACID; HERBACEOUS AGENT; JIANGZHI; LIVER X RECEPTOR ALPHA; PIOGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG GRANULE; ENZYME ACTIVITY; FATTY LIVER; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALS; DRUGS, CHINESE HERBAL; FATTY LIVER; HYPOLIPIDEMIC AGENTS; LIVER; MALE; ORPHAN NUCLEAR RECEPTORS; RATS; RATS, WISTAR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 80053204882     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20110911     Document Type: Article

References (25)

1. Nakamuta M, Fujino T, Yada R, Yada M, Yasutake K, Yoshimoto T, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Enjoji M. Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. Int J Mol Med. 2009; 23(5): 603-608.
2. Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res. 2008; 38(11): 1122-1129.
3. Moya M, Gomez-Lechon MJ, Castell JV, Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact. 2010; 184(3): 376-387.
4. Zheng PY, Ma ZS, Liu T, Xing LJ, Ji G. Effect of Jiangzhi granulas on serum leptin and liver leptin receptor mRNA of nonalcoholic fatty liver disease rat. Zhongguo Zhong Yi Yao Xin Xi Za Zhi. 2008; 15 (6): 36-38.
5. Zhang L, Liu T, Wang M, Xing LJ, Ji G, Zheng PY. Effect of Jiangzhi granula on leptin and leptin receptor of hypothalamus in rats with nonalcoholic liver disease. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2009; 19(2) 8891.
6. Zheng PY, Zhang L, Liu T, Wang M, Xing LJ, Ji G. Effect of Jiangzhi granule on STAT3 expression in hypothalamus of rats with nonalcoholic fatty liver disease. Shi Jie Hua Ren Xiao Hua Za Zhi. 2009; 17 (8): 753-757.
7. Xu ZJ, Fan JG, Wang GL, Ding XD, Tian LY, Zheng XY. Rat model of nonalcoholic steatohepatitis with fibrosis by a fat-rich diet. Shi Jie Hua Ren Xiao Hua Za Zhi. 2002; 10 (4): 392-396.
8. Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit. 2006; 12(1): RA23-RA26.
9. Fan JG, Zeng MD. Fatty liver diseases. Beijing: People's Medical Publishing House. 2005: 118.
10. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002; 17 Suppl: S186-S190.
11. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA. 1998; 95(8): 4333-4337.
12. Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. J Biol Chem. 2000; 275(42): 32379-32382.
13. Chakravarty K, Leahy P, Becard D, Hakimi P, Foretz M, Ferre P, Foufelle F, Hanson RW. Sterol regulatory element-binding protein-1c mimics the negative effect of insulin on phosphoenolpyruvate carboxykinase (GTP) gene transcription. J Biol Chem. 2001; 276 (37): 34816-34823.
14. Foretz M, Guichard C, Ferre P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA. 1999; 96(22): 12737-12742.
15. Shimano H. SREBPs: novel aspects of SREBPs in the regulation of lipid synthesis. FEBS J. 2009; 276 (3): 615.
16. McPherson R, Gauthier A. Molecular regulation of SREBP function: the Insig-SCAP connection and isoformspecific modulation of lipid synthesis. Biochem Cell Biol. 2004; 82(1): 201-211.
17. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006; 116(3): 607-614.
18. Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med. 2005; 353(6): 604-615.
19. Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem. 2007; 282(1): 743-751.
20. Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, Silverstein RL, Xie W. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. 2008; 134(2): 556-567.
21. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem I, Pettersson S, Gustafsson JA. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest. 2001; 107(5): 565-573.
22. Bobard A, Hainault I, Ferre P, Foufelle F, Bossard P. Differential regulation of sterol regulatory element-binding protein 1c transcriptional activity by insulin and liver X receptor during liver development. J Biol Chem. 2005; 280(1): 199-206.
23. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/ refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem. 2002; 277(11): 9520-9528.
24. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13(1): 134-141.
25. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol. 2006; 44(2): 253-261.